Alumis shares are trading lower. The company presented the 28-week open label extension period data from its Phase 2 STRIDE trial of ESK-001.
Portfolio Pulse from Benzinga Newsdesk
Alumis shares are experiencing a decline following the presentation of data from the 28-week open label extension period of its Phase 2 STRIDE trial for ESK-001.
September 27, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Alumis shares are trading lower after the company presented data from its Phase 2 STRIDE trial of ESK-001. The market may be reacting to the trial results, which could have implications for the drug's future development and approval.
The decline in Alumis shares suggests that investors may have concerns about the data presented from the Phase 2 STRIDE trial. This could impact the perceived potential of ESK-001, affecting the company's future prospects and stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90